Comment: The findings in this randomized controlled trial of 5,804 elderly participants are unequivocal: after a mean follow-up of 42 months, pravastatin demonstrated absolutely no difference in cognitive decline across any domain—including executive function, processing speed, or memory. It also celebrates a 24% RRR in cardiovascular mortality while the Absolute Risk Reduction (ARR) was a […]
Comment: This UK Biobank cohort study highlights a conflict between the narrative of statins as a vascular panacea and the documented reality that their use is associated with a 19% increased risk of incident Alzheimer’s disease (HR = 1.19). Looking carefully at the “protective” finding in APOE ε 4 homozygotes (HR = 0.72), there are […]
Comment: This observational MESA study highlights the stark conflict between the idea that early HRT initiation saves lives and the more likely textbook manifestation of healthy user bias impacting outcomes of medical efficacy. Unfortunately the study does not have the data on the formulation used (oral, topical, vaginal), however given the time of intake (2000-2002), […]
Comment: A fundamental conflict exists between the perception of colonoscopy as a “perfectly safe” routine screening and the dramatic iatrogenic escalation that occurs once a procedure becomes therapeutic. While the corrected data for diagnostic perforation is a negligible 0.03%, this “safety halo” disappears the moment a polyp is identified for removal. The human clinical data […]
Comment: There is an assumption that specific routes of hormone therapy (MHT) offer a safe harbor from cardiovascular risk, yet this systematic review of over 5.5 million women identifies a profound disconnect between biochemical promise and systemic biological reality. While early initiation is frequently justified by observational data, we should recognize that these perceived benefits […]
Comment: This systematic review of 33 studies and over 2.5 million women reveals a critical tension between biochemical plausibility and actual clinical outcomes, at least for oral dosing. While observational data suggests early initiation reduces coronary heart disease, we should recognize that some of these findings are likely compromised by Healthy User Bias—where healthier women […]
Comment: A central discrepancy revealed in this research is the failure of Z-drugs, or specifically zolpidem, to deliver on their promise of clinical safety. Despite conventional wisdom suggesting they are a safer class, the data confirms that sedative-hypnotic users as a whole faced a significantly higher mortality risk than non-users. This human clinical data provides […]
Comment: A central issue in sleep medicine is the conflict between the risk of not sleeping, and the risk of taking sedative-hypnotics to help sleep. Most people assume medication induced sleep is better than not sleeping. This 15-year prospective data confirms that daily usage is associated with nearly three times the hazard of death compared […]
Comment: This is another in a growing group of studies showing a correlation between levothyroxine (synthetic T4) use and increased cancer risk. What makes this analysis particularly compelling is the direct comparison between treated and untreated patients with hypothyroidism. While we must respect the limitations of observational data, we must also be pragmatic: we are […]
Comment: A hazard ratio of 1.17 for all-cause mortality is a statistic that shouldn’t be ignored, but unfortunately is. It translates to 45 excess deaths for every 1,000 patients treated. But the most concerning aspect of this data is the graded relationship: the longer the exposure, the higher the risk of death. This dose-response curve […]
